- Home
- TSHA vs INBX Comparison
TSHA vs INBX Comparison
Compare TSHA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | INBX |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.7M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | TSHA | INBX |
|---|---|---|
| Price | $4.60 | $71.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $11.11 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 2.8M | 162.3K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,773,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,228.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.28 | ★ 550.00 |
| 52 Week Low | $1.13 | $10.81 |
| 52 Week High | $6.02 | $94.57 |
Technical Indicators
Market Signals| Indicator | TSHA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 48.04 |
| Support Level | $4.33 | $57.30 |
| Resistance Level | $4.72 | $85.97 |
| Average True Range (ATR) | 0.28 | 4.62 |
| MACD | 0.04 | 0.45 |
| Stochastic Oscillator | 70.00 | 62.16 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.